Genscript BiotechGNNSF 66 Beneish M-Score is -3.07 as of Jul. 04, 2026. GuruFocus rates GNNSF with a GF Score™ of 66/100 and a GF Value™ of $2.48 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 829 Biotechnology companies, Genscript Biotech ranks better than 76.6% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -3.07 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Genscript Biotech's Beneish M-Score or its related term are showing as below:
GNNSF'
s Beneish M-Score Range Over the Past 10 Years
Min: -3.44 Med: -2.41 Max: 4.78
Current: -3.07
During the past 12 years, the highest Beneish M-Score of Genscript Biotech was 4.78. The lowest was -3.44. And the median was -2.41.
Genscript Biotech Beneish M-Score Related Terms
Genscript Biotech Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNNSF vs VRTX, REGN, ALNY: Beneish M-Score Comparison
For the Biotechnology subindustry, Genscript Biotech's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech Beneish M-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Genscript Biotech for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 0.7571
+
0.528 * 0.794
+
0.404 * 0.8923
+
0.892 * 1.614
+
0.115 * 1.075
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.6978
+
4.679 * -0.17686
-
0.327 * 0.9856
=
-3.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(77.67 / (77.67 + 602.838))
/
(74.039 / (74.039 + 623.275))
=
0.114135
/
0.106177
=
1.075
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-532.83 - 0
-
325.522)
/
4853.277
=
-0.17686
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Genscript Biotech has a M-score of -3.07 suggests that the company is unlikely to be a manipulator.
Genscript Biotech (GNNSF) has a Beneish M-Score of -3.07 as of Jul. 04, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Genscript Biotech and its competitors. According to the industry distribution chart, Genscript Biotech ranks #194 out of 829 companies in the Biotechnology industry, placing it in the top 23.4%.
Is Genscript Biotech's Beneish M-Score too high?
Genscript Biotech's current Beneish M-Score is -3.07. Based on the distribution chart, Genscript Biotech ranks #194 out of 829 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genscript Biotech has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #194 out of 829 companies for Beneish M-Score. This places Genscript Biotech in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Genscript Biotech and its competitors. Genscript Biotech's current Beneish M-Score is -3.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.48, compared to a current price of $1.60 — trading 35.5% below its estimated fair value. The current Beneish M-Score is -3.07. Genscript Biotech's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Beneish M-Score is -3.07 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued.
The current stock price of $1.60 is trading 35.5% below its estimated GF Value™ of $2.48.
GuruFocus considers Genscript Biotech to be Significantly Undervalued.
Key valuation signals for GNNSF:
Beneish M-Score: -3.07
GF Value™: $2.48 vs. price of $1.60 (35.5% below fair value)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
66GF Score
Get the complete analysis for GNNSF
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
